Cetuximab and panitumumab, monoclonal antibodies direct against the epidermal growth factor receptor (EGFR) are a therapeutic option for mCRC patients wild type for KRAS and NRAS genes. However, only a subset of mCRC patients receives clinical benefit from these therapies due to the development of resistance mechanisms. HER2 gene amplification or HER2 activating mutations have been implicated as resistance mechanisms to anti-EGFR therapies. However, little is known about the role of HER2 in cancer resistance to anti-EGFR antibodies.
Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models
Castellone M D;
2018
Abstract
Cetuximab and panitumumab, monoclonal antibodies direct against the epidermal growth factor receptor (EGFR) are a therapeutic option for mCRC patients wild type for KRAS and NRAS genes. However, only a subset of mCRC patients receives clinical benefit from these therapies due to the development of resistance mechanisms. HER2 gene amplification or HER2 activating mutations have been implicated as resistance mechanisms to anti-EGFR therapies. However, little is known about the role of HER2 in cancer resistance to anti-EGFR antibodies.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
